Me Medicine Vs. We Medicine: Reclaiming Biotechnology for the Common Good (Hardbound - 2013)
In stock
Only 5 left
SKU
9780231159746_SAP
Special Price ₹1,923.00 Regular Price ₹2,564.00
Ships in 1-2 Days!
About the Book
Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology.
Personalized healthcare--or what the award-winning author Donna Dickenson calls "Me Medicine"--is radically transforming our longstanding "one-size-fits-all" model. Technologies such as direct-to-consumer genetic testing, pharmacogenetically developed therapies in cancer care, private umbilical cord blood banking, and neurocognitive enhancement claim to cater to an individual's specific biological character, and, in some cases, these technologies have shown powerful potential. Yet in others they have produced negligible or even negative results. Whatever is behind the rise of Me Medicine, it isn't just science. So why is Me Medicine rapidly edging out We Medicine, and how has our commitment to our collective health suffered as a result? In her cogent, provocative analysis, Dickenson examines the economic and political factors fueling the Me Medicine phenomenon and explores how, over time, this paradigm shift in how we approach our health might damage our individual and collective well-being. Historically, the measures of "We Medicine," such as vaccination and investment in public-health infrastructure, have radically extended our life spans, and Dickenson argues we've lost sight of that truth in our enthusiasm for "Me Medicine." Dickenson explores how personalized medicine illustrates capitalism's protean capacity for creating new products and markets where none existed before--and how this, rather than scientific plausibility, goes a long way toward explaining private umbilical cord blood banks and retail genetics. Drawing on the latest findings from leading scientists, social scientists, and political analysts, she critically examines four possible hypotheses driving our Me Medicine moment: a growing sense of threat; a wave of patient narcissism; corporate interests driving new niche markets; and the dominance of personal choice as a cultural value. She concludes with insights from political theory that emphasize a conception of the commons and the steps we can take to restore its value to modern biotechnology.
ISBN13 | 9780231159746 |
---|---|
Product Name | Me Medicine Vs. We Medicine: Reclaiming Biotechnology for the Common Good (Hardbound - 2013) |
Price | ₹2,564.00 |
Original Price | USD 29.95 |
Author | Donna Dickenson |
Publisher | Columbia University Press |
Publication Year | 2013 |
Subject | Medical, Nursing and Health Sciences |
Binding | Hardbound |
Language | English |
Pages | 296 |
Weight | 0.536000 |
Write Your Own Review
-
Icon
-
Icon
-
Icon
Lowest Price
Trusted Since 1977
-
Icon
payment method
Secure payment
Featured Books
Black Feminist Thought: Knowledge, Consciousness, and the Politics of Empowerment (Paperback - 2017)
Special Price ₹675.00 Regular Price ₹750.00
Management for UPSC (Main) and Other Competitive Examinations (Paper I) (Paperback - 2022)
Special Price ₹536.00 Regular Price ₹595.00
Joothan: A Dalit's Life (Paperback - 2007)
Special Price ₹413.00 Regular Price ₹550.00
Login and Registration Form